Jane Street
URGN icon

Jane Street’s UroGen Pharma URGN Stock Holding History

Jane Street’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$771K Buy
42,900
+25,000
+140% +$501K ﹤0.01% 7064
2025
Q4 		$419K Sell
17,900
-26,200
-59% -$568K ﹤0.01% 8096
2025
Q3 		$880K Sell
44,100
-44,600
-50% -$801K ﹤0.01% 6595
2025
Q2 		$1.22M Buy
+88,700
New +$851K ﹤0.01% 5257
2023
Q4 		– Sell
-14,100
Closed -$198K – 9843
2023
Q3 		$198K Buy
+14,100
New +$226K ﹤0.01% 7629
2020
Q4 		– Sell
-25,000
Closed -$482K – 8136
2020
Q3 		$482K Sell
25,000
-100
-0.4% -$2.26K ﹤0.01% 5209
2020
Q2 		$656K Buy
+25,100
New +$613K ﹤0.01% 4669

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Jane Street's URGN Position: Q4 2025 in Review

Jane Street sold out of UroGen Pharma (URGN) in Q4 2025, closing a stake of 328,419 shares — an estimated $7.12M sold.

Jane Street first reported a position in URGN in Q2 2018 and held it in 16 quarters. The position peaked at $6.55M in Q3 2025. 167 funds tracked by Wall St. Rank hold URGN as of Q4 2025.

  • Jane Street reported no remaining UroGen Pharma position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 328,419 UroGen Pharma shares in Q4 2025, an estimated $7.12M.
  • Jane Street first reported a position in UroGen Pharma in Q2 2018 and held it in 16 quarters.
  • Jane Street's UroGen Pharma position peaked at $6.55M in Q3 2025.
  • 167 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.